Patents Examined by Marianne P. Allen
  • Patent number: 10293027
    Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: May 21, 2019
    Assignee: Salk Institute for Biological Studies
    Inventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
  • Patent number: 10293051
    Abstract: The invention relates to the field of pharmaceutical formulations. More particularly, it is directed to xyloglucan hydrogels comprising Fibroblast Growth Factor 18 (FGF-18) compounds and methods of producing such hydrogels. The hydrogels of the invention can be used, once formed in situ, for the treatment of cartilage disorders such as osteoarthritis or cartilage injury.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: May 21, 2019
    Assignee: ARES TRADING S.A.
    Inventors: Caterina Lo Presti, Donatella Bulone, Clelia Dispenza
  • Patent number: 10288616
    Abstract: Methods are provided for treating a gastric cancer patient. A specific Met fragment peptide is precisely quantitated by SRM-mass spectrometry directly in gastric tumor cells collected from gastric tumor tissue that was obtained from the cancer patient and compared to a reference level. If the Met peptide is below the reference level a second therapeutic regimen is used to treat the patient whereas if the Met peptide is above the reference level then a first therapeutic regimen combining, for example, the second regimen with one or more Met inhibitor therapeutic agents may be used to treat the patient.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: May 14, 2019
    Assignees: Expression Pathology, Inc., The University Of Chicago
    Inventors: Daniel Catenacci, Todd Hembrough, Fabiola Cecchi, Wei-Li Liao
  • Patent number: 10279013
    Abstract: Provided herein are methods for treating an animal using a composition that includes active IGF. The methods include treating an animal at risk of having an infection caused by an infectious agent, treating an animal having an infection, and treating a symptom associated with an infection. In one embodiment, the infectious agent is a virus. In one embodiment, the administering includes daily administration of at least 0.05 nanograms of active IGF-1 per kilogram bodyweight of the animal daily (ng/kg), at least 0.1 ng/kg, at least 2 ng/kg, at least 5 ng/kg, or at least 10 ng/kg.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 7, 2019
    Assignee: PURETEIN BIOSCIENCE LLC
    Inventors: Brett Casebolt, Chad D. Hagen, Robert Eldon Musser
  • Patent number: 10279075
    Abstract: Preparations containing hepatocyte growth factor (HGF) and hyaluronic acid (HA) and methods of making and using same. The HGF and HA preparations can be prepared together in solution as an injectable fluid without gelatinization, or impregnated within a porous hydrophilic matrix material with, or without, cross-linking of the HA with the matrix material. The preparations can be used as a dermal filler or to generate and promote healing of cartilage, vertebral discs, connective tissues such as tendons and ligaments and bone in vivo.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: May 7, 2019
    Assignee: NUTECH MEDICAL, INC.
    Inventor: Howard P. Walthall, Jr.
  • Patent number: 10258677
    Abstract: The present invention comprises compositions, methods, and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: April 16, 2019
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Glenn Dranoff
  • Patent number: 10261087
    Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor (VEGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: April 16, 2019
    Assignee: CELLTREND GMBH
    Inventors: Harald Heidecke, Kai Schulze-Forster
  • Patent number: 10259870
    Abstract: The present invention provides antibodies that bind to ANGPTL8 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human ANGPTL8 with high affinity. The antibodies of the invention may be fully human antibodies. The antibodies of the invention are useful for the treatment of various diseases or disorders characterized in part by elevated blood triglyceride levels.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: April 16, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy, David R. Buckler
  • Patent number: 10246507
    Abstract: A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: April 2, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seung Hyun Lee, Soo Yeon Jung, Bo Gyou Kim, Seung Ja Oh, Ji Min Lee
  • Patent number: 10239926
    Abstract: As described herein, the present invention features compositions comprising an HGF/IgG complex and methods of using such compositions to reduce ischemic reperfusion injury.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 26, 2019
    Assignee: The University of Vermont and State Agriculture College
    Inventor: Jeffrey Spees
  • Patent number: 10226504
    Abstract: The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble Fc?RIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: March 12, 2019
    Assignee: SUPPREMOL GMBH
    Inventors: Peter Sondermann, Thomas Pohl
  • Patent number: 10213485
    Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: February 26, 2019
    Assignee: KRINGLE PHARMA INC.
    Inventors: Kazuhiro Fukuta, Hayao Inoue
  • Patent number: 10203343
    Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor (EGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an epidermal growth factor receptor inhibitor.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: February 12, 2019
    Assignee: CELLTREND GMBH
    Inventors: Harald Heidecke, Kai Schulze-Forster
  • Patent number: 10202459
    Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 12, 2019
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, UNIVERSITY OF ULSAN, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, PHAROSGEN
    Inventors: Youngro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang
  • Patent number: 10179810
    Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: January 15, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Paul Adam, Eric Borges, Robert Rauchenberger, Gabriela Wochnik-Veltrup
  • Patent number: 10167329
    Abstract: This invention is in the field of IGF-1 modifications. In particular, it relates to modified IGF-polypeptides and modified IGF-1 precursor polypeptides wherein the cleavage of E-peptide is prevented. The invention also relates to the use of such polypeptides for treating muscle diseases and disorders.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: January 1, 2019
    Assignee: Novartis AG
    Inventors: Mara Fornaro, Thomas Huber, Mauro Zurini
  • Patent number: 10160804
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: December 25, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T. L. Smith, Randall C. Schatzman, Mark Litton, John Latham
  • Patent number: 10159711
    Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: December 25, 2018
    Assignee: Salk Institute for Biological Studies
    Inventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
  • Patent number: 10150811
    Abstract: Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: December 11, 2018
    Assignee: AERPIO THERAPEUTICS, INC.
    Inventors: Kevin Peters, Robert Shalwitz
  • Patent number: 10138283
    Abstract: Modified bovine G-CSF polypeptides and uses thereof are provided.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: November 27, 2018
    Assignees: AMBRX, INC., ELANCO US INC.
    Inventors: Anna-Maria A. Hays Putnam, Nick Knudsen, Thea Norman, Alan Koder, Vadim Kraynov, Lillian Ho, Peter C. Canning